Novo Nordisk A/S

DK

NOVO

Health Care

125.26 ₽

Current price

Hold
125.26 ₽

Target price 00%

Ranks rating

76

  • Position in sub-industry

    289 / 1328

  • Position in country

    61 / 253

  • Return on Assets, %

    30.2

    -2.7

  • Net income margin, %

    33.3

    2.8

  • EBITDA margin, %

    41.9

    10.8

  • Debt to Equity, %

    25.3

    19.2

  • Intangible assets and goodwill, %

    19.2

    3.6

  • Revenue CAGR 3Y, %

    22.3

    8.5

  • Total Equity change 1Y, %

    31.2

    0

  • Revenue Y, % chg

    35.2

    0.5

  • P/E

    46.8

    22.7

  • P/BV

    36.5

    1.5

  • P/S

    12.9

    2.3

  • EV/S

    13.1

    2.4

  • EV/EBITDA

    27.7

    7.4

  • Average Analyst recommendation

    Buy

    Buy

  • Average upside forecasts, %

    12

    51.3

  • Forward P/E

    36

    15.6

  • Dividend Yield, %

    1

    1.7

  • Forward Dividend Yield, %

    1.3

    0.2

  • Expected dividend per share

    1.7

    0

  • Payout Ratio, %

    50.1

    30.3

  • Dividend Ex Date

    2024-03-22

Get an analytical review of this company

Competitors

Ranks

  • Novo Nordisk A/S

    00%

  • H Lundbeck A/S

    00%

  • AstraZeneca PLC

    00%

  • ALK-Abello A/S

    00%

  • Eli Lilly and Co

    00%

  • Roche Holding AG

    00%

  • Bristol-Myers Squibb Co

    00%

  • Novartis AG

    00%

  • Johnson & Johnson

    00%

  • Merck & Co Inc

    00%

Ready-made portfolio of the best Russian stocks

  • Created by artificial intelligence
  • Verified by analysts
  • Available even to beginners

Company information

  • Country

    Denmark

  • Sector

    Health Care

  • Industry group

    Pharmaceuticals, Biotechnology & Life Sciences

  • Industry

    Pharmaceuticals

  • Sub-sector

    Health Care

  • Capitalization (millions of $)

    434707.5

  • Ticker

    NVO.N

  • ISIN

    US6701002056

  • IPO date

    1974-05-17

  • Availability on Russian exchanges

    No

  • Reporting for

    2024-01-31

  • Date fact. publication of reports

    2023-12-31

Company Description

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

A step towards better analytics

  • find the best promotions through the Screener
  • keep an eye on stock valuation
  • download detailed reports

and much more after free registration

Registration

More convenient from your phone? Download: